{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:56:53Z","timestamp":1760954213872},"reference-count":17,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.vaccine.2017.02.057","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T01:48:39Z","timestamp":1489456119000},"page":"1865-1872","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Anuradha","family":"Madan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murdo","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhar","family":"Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Friel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Schuind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.02.057_b0005","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.02.057_b0010","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3201\/eid2206.151752","article-title":"Human Infection with Influenza A(H7N9) Virus during 3 Major Epidemic Waves, China, 2013\u20132015","volume":"22","author":"Wu","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0015","doi-asserted-by":"crossref","first-page":"20475","DOI":"10.2807\/ese.18.19.20475-en","article-title":"Preliminary inferences on the age-specific seriousness of human disease caused by avian influenza A(H7N9) infections in China, March to April 2013","volume":"18","author":"Cowling","year":"2013","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.02.057_b0020","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jcv.2013.09.004","article-title":"Age-specific and sex-specific morbidity and mortality from avian influenza A(H7N9)","volume":"58","author":"Dudley","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2017.02.057_b0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0140-6736(13)61207-6","article-title":"Human infection with avian influenza A H7N9 virus: an assessment of clinical severity","volume":"382","author":"Yu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.02.057_b0030","first-page":"68","article-title":"Immunosenescence and challenges of vaccination against influenza in the aging population","volume":"3","author":"Reber","year":"2012","journal-title":"Aging Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.02.057_b0040","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.vaccine.2017.01.054","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: a phase I\/II, observer blind, randomized, controlled trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.057_b0045","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0050","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiw414","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults","author":"Madan","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0060","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/infdis\/jiq174","article-title":"Immunogenicity profile of a 3.75-\u03bcg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial","volume":"203","author":"Heijmans","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2334-14-142","article-title":"Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults","volume":"14","author":"Gillard","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0070","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1016\/j.vaccine.2015.06.053","article-title":"AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes","volume":"33","author":"Mallett","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.057_b0075","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.vaccine.2009.01.136","article-title":"Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults","volume":"27","author":"McElhaney","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.057_b0080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1086\/590435","article-title":"Better influenza vaccines for older people: what will it take?","volume":"198","author":"McElhaney","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.057_b0085","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T02:39:19Z","timestamp":1658803159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17302700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":17,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0264410X17302700"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}